Solid tumors as second malignancies are not common in children who have been managed for lymphoproliferative disorders. We report a case of adenocarcinoma (AC) of the colon as a second malignancy in a patient who was on maintenance chemotherapy for acute lymphoblastic leukemia (ALL). In children, primary AC of the colon is very rare; colonic AC occurring as a second malignancy in a child is rarer still. A case of AC of the colon following chemotherapy for ALL has not yet been published.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s003839900315 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive value of Bladder EpiCheck in detecting residual tumor before second TUR for non-muscle-invasive bladder cancer.
World J Urol
January 2025
Department of Urology, University of Health Sciences, Bagcilar Training and Research Hospital, Istanbul, 34200, Turkey.
Purpose: As Bladder EpiCheck (BE) is a promising urinary biomarker for diagnosis and follow up of non-muscle-invasive bladder cancer (NMIBC), there are no studies evaluated this tool for second transurethral resection (TUR) indication. We aim to evaluate the performance of BE in predicting residual tumor before second TUR in NMIBC and its effects on clinical decision making.
Methods: A total of 50 patients who were diagnosed with NMIBC and indicated for a second TUR were included in the study prospectively.
Case report: Malignant priapism: penile metastasis from prostate cancer with low serum PSA level.
Front Oncol
January 2025
Department of Urology, Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Penile metastasis originating from prostate cancer is an extremely rare condition, typically associated with a poor prognosis. Therapeutic approaches are not well established and may require individualized adaptation based on clinical assessment. Radiotherapy is commonly utilized to alleviate symptoms.
View Article and Find Full Text PDFCase report: A successful case of targeted immunotherapy for locally advanced pancreatic cancer under non-surgical conditions.
Front Immunol
January 2025
Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Introduction: Locally advanced pancreatic cancer (LAPC) is a borderline unresectable malignancy that presents significant treatment challenges. The management of LAPC remains a complex issue, particularly in patients who are not eligible for surgical resection.
Case: Here, we report the case of a 60-year-old woman diagnosed with LAPC through pathological biopsy who subsequently underwent targeted immunotherapy following the failure of a gemcitabine, oxaliplatin, and S-1 (G&S) chemotherapy regimen.
Management of intrahepatic cholangiocarcinoma: a review for clinicians.
Gastroenterol Rep (Oxf)
January 2025
Department of Health Sciences, University of Piemonte Orientale, Novara, Italy.
Intrahepatic cholangiocarcinoma (iCCA) is an aggressive liver malignancy that arises from second-order biliary epithelial cells. Its incidence is gradually increasing worldwide. Well-known risk factors have been described, although in many cases, they are not identifiable.
View Article and Find Full Text PDFiRGD-Targeted Biosynthetic Nanobubbles for Ultrasound Molecular Imaging of Osteosarcoma.
Int J Nanomedicine
January 2025
Department of Ultrasound, The second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, 518061, People's Republic of China.
Purpose: Osteosarcoma is the most common primary malignant tumor of the bone. However, there is a lack of effective means for early diagnosis due to the heterogeneity of tumors and the complexity of tumor microenvironment. αvβ3 integrin, a crucial role in the growth and spread of tumors, is not only an effective biomarker for cancer angiogenesis, but also highly expressed in many tumor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!